Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)

Inclusion Criteria: * History of exercise-limiting intermittent claudication and peripheral arterial disease with symptoms in one or both legs, of at least 2 months duration with no change in symptom severity in the 2 months prior to screening. * A Doppler-measured ankle-brachial index (ABI) of ≤0.80 or toe-brachial index (TBI) of \<0.70 in at least one leg after 10 minutes of rest. * Limitation in walking secondary to claudication with a mean peak walking time (PWT) of between 1 and 10 minutes on a standardized Gardner protocol for exercise treadmill test (ETT). * Angiographic or equivalent anatomic evidence (MRA) of arterial occlusive disease (\>70%) in the distal common femoral artery or superficial femoral artery and its branches of at least one leg within 12 months prior to screening. * Postmenopausal (females),surgically sterile, or use adequate birth control. Exclusion Criteria: * Presence of significant inflow disease \[defined as \>50% stenosis\] in the distal aorta, common or external iliac as assessed by conventional angiogram, digital subtraction angiography (DSA), or magnetic resonance angiography (MRA) performed \< 1 year prior to screening. * Critical limb ischemia, either chronic or acute ischemia manifested by rest pain, ulceration, or gangrene (Category 4 through 6 of Society for Vascular Surgery \[SVS\] classification \[Rutherford\]). * History of malignant neoplasm (except curable non-melanoma skin malignancies). * Renal failure (serum creatinine \>2.0 mg/dL) or end-stage renal disease(requiring hemodialysis or renal replacement therapy). * Significant hepatic disease (\>3-fold elevation in ALT/AST). * HBV or HCV carriers. * Severe pulmonary disease (e.g. severe chronic obstructive pulmonary disease). * Subjects with Acute Stroke within 6 months prior to screening. * Subjects with uncontrolled diabetes mellitus. * Specific ophthalmologic conditions that preclude retinal photography,vascular lesions of the anterior segment of the eye, proliferative retinopathy, age-related macular degeneration or intra-ocular surgery within 6 months prior to enrollment. * Gross obesity (BMI≥40). * Buerger's disease or other forms of inflammatory arteritis. * Class IV congestive heart failure, as defined by the New York Heart Association or a myocardial infarction within 6 months prior to screening. * Subject with deep vein thrombosis within 3 months prior to screening. * Inability to complete the standardized treadmill protocol for reasons other than claudication including symptoms such as angina, dyspnea, joint pains, or excessive fatigue. * Percutaneous intervention or surgical revascularization in the index lower limb within 6 months prior to enrollment. * Heart angioplasty with or without stent or coronary bypass surgery within the past 6 months. * Participation in a structured exercise treatment protocol within 30 days prior to screen testing. * Subject is planning to participate in a structured exercise treatment protocol during the 180 days following administration of the investigational product. * Participation in a previous gene transfer trial in which the subject received active investigational product (placebo subjects are eligible). * Concurrent or prior participation in another clinical trial within 30 days prior to screen testing. * Chronic use of Cox-2 inhibitors, defined as subjects needing daily use of the agent for more than 30 days prior to screening. * Subject is taking any of the following drugs for life-threatening conditions or as part of a life-sustaining treatment: Cyclosporine (Sandimmune®),Systemic androgens/anabolic steroids, systemic corticosteroids. * History of bleeding diathesis (e.g. hemophilia due to Factor VIII or IX deficiency). * Pregnancy or breast-feeding. * Uncontrolled hypertension or significant hypotension. * Immunodeficiency states (e.g, current HIV positivity, or organ transplant recipient) or subject receiving immunosuppressive medications. * Alcohol or other substance abuse.